All In Biotech

Drug Trial Radar · NCT07603557

Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)

A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

May 6, 2030

Study completion May 6, 2030

Sponsor

Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and autoimmune hemolytic anemia (AIHA).

Conditions

  • Chronic Immune Thrombocytopenia
  • Autoimmune Hemolytic Anemia

Interventions

  • BMS-986353Biological

    Specified dose of specified days

  • Fludarabine PhosphateDrug

    Specified dose of specified days

  • CyclophosphamideDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1 Part A: Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to approximately Month 36
  2. Cohort 1 Part A: Number of participants with serious AEs (SAEs)Time frame: Up to approximately Month 36
  3. Cohort 1 Part A: Number of participants with AEs of special interest (AESI)Time frame: Up to approximately Month 36
  4. Cohort 1 Part A: Number of participants with clinically significant laboratory abnormalitiesTime frame: Up to approximately Month 36
  5. Cohort 1 Part B: Hematologic Complete Response (CR)Time frame: Up to approximately Month 6

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • Local Institution - 101

    Boston, Massachusetts

  • Local Institution - 103

    Houston, Texas

  • Local Institution - 102

    Seattle, Washington

  • Local Institution - 201

    Odense, Denmark

  • Local Institution - 302

    Erlangen, Germany

  • Local Institution - 301

    Magdeburg, Saxony-Anhalt, Germany

  • Local Institution - 402

    Sheffield, United Kingdom

  • Local Institution - 401

    London, Greater London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.